Company Moberg Pharma AB

MOB

SE0020353928

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:37 2024-04-25 am EDT			5-day change	1st Jan Change
34.14 ^SEK	-1.04%		+25.70%	+124.61%

Apr. 08	Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	CI
Feb. 26	Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	CI

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.

Number of employees: 10

Managers	Title	Age	Since
Anna Ljung CEO	Chief Executive Officer	44	05-12-31
Mark Beveridge DFI	Director of Finance/CFO	46	14-12-31
Anders Bröijersén CTO	Chief Tech/Sci/R&D Officer	60	22-12-31
Gunilla Wengström SAM	Sales & Marketing	62	19-01-07
Annica Magnusson LAW	General Counsel	61	19-01-07

Members of the board	Title	Age	Since
Anders Lundmark BRD	Director/Board Member	66	22-05-15
Håkan Wallin BRD	Director/Board Member	62	23-05-15
Nikolaj Sørensen BRD	Director/Board Member	52	20-12-31
Kerstin Valinder-Strinnholm CHM	Chairman	64	22-05-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	28,407,452	19,288,290 ( 67.90 %)	445,974 ( 1.570 %)	67.90 %

Name	Equities	%	Valuation
FRAM Capital GmbH 0.5280 %	150,000	0.5280 %	317 042 kr
FCG Fonder AB 0.2868 %	81,477	0.2868 %	172 211 kr
Storebrand Asset Management AS 0.0544 %	15,463	0.0544 %	32 683 kr
Skandia Fonder AB 0.005639 %	1,602	0.005639 %	3 386 kr
Case Kapitalförvaltning AB 0.004041 %	1,148	0.004041 %	2 426 kr

Name	Equities	%	Valuation
FRAM Capital GmbH 0.9921 %	173,323	0.9921 %	48 629 kr
Storebrand Asset Management AS 0.0354 %	6,179	0.0354 %	1 734 kr

Moberg Pharma AB

Gustavslundsvägen 50 5th Floor

167 51, Bromma

+46 8 52 23 07 00

http://www.mobergderma.se

Name	Category and Sector
Moberg Derma Incentives AB
ONCOZENGE AB	Pharmaceuticals: Major

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
MOBERG PHARMA AB	+124.61%	88.59M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.55%	358B
MERCK & CO., INC.	+19.27%	322B
ABBVIE INC.	+8.01%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.65%	149B
AMGEN INC.	-6.83%	146B

Other Pharmaceuticals